Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,472
datasets available to search
ShareScore release 0.9.0
Dataset results
1,472 results for “EGFR”
PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT02994888. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel
ClinicalTrials.gov study NCT00768131. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer
ClinicalTrials.gov study NCT02151721. IPD Sharing: YES. Countries: 1. Publications: 0.
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
ClinicalTrials.gov study NCT02906150. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT01919879. IPD Sharing: Not stated. Countries: 1. Publications: 0.
High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
ClinicalTrials.gov study NCT02404675. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
ClinicalTrials.gov study NCT06363734. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
ClinicalTrials.gov study NCT03758287. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers
ClinicalTrials.gov study NCT04946968. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
ClinicalTrials.gov study NCT01221077. IPD Sharing: NO. Countries: 6. Publications: 0.
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
ClinicalTrials.gov study NCT05060796. IPD Sharing: NO. Countries: 1. Publications: 0.
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
ClinicalTrials.gov study NCT06945705. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma
ClinicalTrials.gov study NCT05165355. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exo
ClinicalTrials.gov study NCT04576208. IPD Sharing: YES. Countries: 0. Publications: 0.
Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
ClinicalTrials.gov study NCT01410214. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
ClinicalTrials.gov study NCT03529084. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
ClinicalTrials.gov study NCT06043817. IPD Sharing: Not stated. Countries: 7. Publications: 0.
Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies
ClinicalTrials.gov study NCT04878692. IPD Sharing: Not stated. Countries: 1. Publications: 0.
TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors
ClinicalTrials.gov study NCT04976218. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
ClinicalTrials.gov study NCT06369259. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.